Barclays PLC Buys 28,208 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Barclays PLC increased its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 281.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,218 shares of the company’s stock after buying an additional 28,208 shares during the quarter. Barclays PLC owned about 0.08% of Mineralys Therapeutics worth $463,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in shares of Mineralys Therapeutics during the 3rd quarter worth $110,000. China Universal Asset Management Co. Ltd. lifted its position in Mineralys Therapeutics by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,564 shares of the company’s stock worth $116,000 after purchasing an additional 3,732 shares during the period. Federated Hermes Inc. grew its stake in Mineralys Therapeutics by 100.0% during the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $140,000 after buying an additional 6,000 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in Mineralys Therapeutics in the 2nd quarter valued at about $145,000. Finally, PDT Partners LLC acquired a new position in shares of Mineralys Therapeutics in the 3rd quarter valued at approximately $148,000. Institutional investors own 84.46% of the company’s stock.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, CEO Jon Congleton sold 15,271 shares of the company’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $13.52, for a total value of $206,463.92. Following the completion of the transaction, the chief executive officer now owns 895,941 shares of the company’s stock, valued at $12,113,122.32. This represents a 1.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $13.57, for a total value of $145,972.49. Following the completion of the transaction, the chief financial officer now owns 236,854 shares of the company’s stock, valued at $3,214,108.78. This represents a 4.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 51,510 shares of company stock valued at $735,431 in the last quarter. Insiders own 33.24% of the company’s stock.

Mineralys Therapeutics Stock Down 0.5 %

Shares of MLYS stock opened at $12.25 on Friday. The business has a fifty day simple moving average of $12.86 and a 200 day simple moving average of $12.54. The company has a market cap of $609.67 million, a P/E ratio of -3.75 and a beta of 1.56. Mineralys Therapeutics, Inc. has a twelve month low of $7.95 and a twelve month high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its earnings results on Monday, November 11th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same period in the previous year, the business earned ($0.57) earnings per share. As a group, equities research analysts anticipate that Mineralys Therapeutics, Inc. will post -3.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Mineralys Therapeutics in a research report on Tuesday, November 12th.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.